307 related articles for article (PubMed ID: 27120499)
1. Cancer drug related cardiotoxicity during breast cancer treatment.
Giordano G; Spagnuolo A; Olivieri N; Corbo C; Campagna A; Spagnoletti I; Pennacchio RM; Campidoglio S; Pancione M; Palladino L; Villari B; Febbraro A
Expert Opin Drug Saf; 2016 Aug; 15(8):1063-74. PubMed ID: 27120499
[TBL] [Abstract][Full Text] [Related]
2. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G; Lancellotti P; Kim SB
Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment-induced cardiotoxicity.
Martel S; Maurer C; Lambertini M; Pondé N; De Azambuja E
Expert Opin Drug Saf; 2017 Sep; 16(9):1021-1038. PubMed ID: 28697311
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
5. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.
Ahmed SH; Moussa Sherif DE; Fouad Y; Kelany M; Abdel-Rahman O
Expert Opin Drug Saf; 2016 Jul; 15(7):911-23. PubMed ID: 27007468
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
Leung HW; Chan AL
Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
[TBL] [Abstract][Full Text] [Related]
9. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
Dent SF; Morse A; Burnette S; Guha A; Moore H
Curr Oncol Rep; 2021 Aug; 23(11):128. PubMed ID: 34453232
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
12. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
Lancellotti P; Anker SD; Donal E; Edvardsen T; Popescu BA; Farmakis D; Filippatos G; Habib G; Maggioni AP; Jerusalem G; Galderisi M
Eur Heart J Cardiovasc Imaging; 2015 May; 16(5):466-70. PubMed ID: 25744342
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
14. Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy.
Abdel-Rahman O
Breast Cancer; 2018 Nov; 25(6):723-728. PubMed ID: 29882200
[TBL] [Abstract][Full Text] [Related]
15. CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS.
Kozhukhov SM; Dovganych NV; Smolanka II; Lygyrda OF; Bazyka OY; Lyalkin SA; Ivankova OM; Yarinkina OA; Tkhor NV
Probl Radiac Med Radiobiol; 2021 Dec; 26():498-512. PubMed ID: 34965569
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
Gramatyka M
Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of Contemporary Breast Cancer Treatments.
Lee Chuy K; Yu AF
Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
19. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity: trastuzumab and cancer survivors.
Patanè S
Int J Cardiol; 2014 Dec; 177(2):554-6. PubMed ID: 25205483
[No Abstract] [Full Text] [Related]
[Next] [New Search]
